Pandemic-related resilience in HPV vaccination programmes – Perspectives from selected countries in Africa on what it will take to vaccinate 90 % of girls by 2030
•The COVID-19 pandemic disrupted HPV vaccination particularly.•School closures and targeted misinformation were damaging.•Successful recovery efforts needed new relationships and investments.•Key allies were education sector and professional societies.•Key investments were tailored service intensifi...
Saved in:
Published in: | Vaccine Vol. 42; pp. S33 - S36 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Kidlington
Elsevier Ltd
11-07-2024
Elsevier Limited |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •The COVID-19 pandemic disrupted HPV vaccination particularly.•School closures and targeted misinformation were damaging.•Successful recovery efforts needed new relationships and investments.•Key allies were education sector and professional societies.•Key investments were tailored service intensification and communications.
The COVID-19 pandemic resulted in widespread disruptions to primary health care and other sectors, halting the majority of routine immunisation services and particularly impacting newer, less routinized HPV vaccine programmes. We present a series of five country case studies, drawing directly from frontline experiences in Côte d’Ivoire, Kenya, Liberia, Zambia, and Senegal to explore potential barriers and enablers of national HPV vaccine programme resiliency in the aftermath of a pandemic. A series of common themes emerged, articulating common challenges to maintaining HPV vaccine programmes, common factors that supported programme resilience, and common themes of resource needs to rebuild stronger routine immunisation programmes to face future threats. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0264-410X 1873-2518 1873-2518 |
DOI: | 10.1016/j.vaccine.2023.08.057 |